Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications

  • Yanan Yan1
  • Tianhao Teng1
  • Xinying Luo1
  • Jingfeng Liu2,3,4
  • Jianmin Wang1,2,3
4 affiliations
  1. 1Innovation Center for Cancer Research, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
  2. 2Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fujian Cancer Hospital
  3. 3NHC Key Laboratory of Cancer Metabolism, Fujian Cancer Hospital
  4. 4Department of Hepatopancreatobiliary Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
Read full textPDFDOICite

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy characterized by pronounced cellular, spatial, and metabolic heterogeneity. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) are beginning to resolve this complexity by linking malignant, immune, stromal, and metabolic states to their tissue context. This review synthesizes recent single-cell and spatial studies of iCCA across four spatial contexts: adaptive immune regions containing tertiary lymphoid structures (TLSs), barriers formed by stromal and myeloid cells at the invasive front, myeloid niches shaped by hypoxia, and metastatic ecosystems involving immune and stromal cells. These niches connect tumor heterogeneity with immune regulation, stromal remodeling, metabolic adaptation, and therapeutic vulnerability. We also evaluate how crosstalk between metabolism and immunity shapes macrophage polarization, T-cell dysfunction, and treatment response, while distinguishing computationally inferred interactions from functionally supported mechanisms. The field is therefore moving from cataloging additional cell states and spatial niches toward establishing which ecosystem features are reproducible across cohorts, mechanistically supported, clinically measurable, and informative for treatment response. Current evidence supports a view of iCCA as a spatially organized and metabolically regulated tumor ecosystem that can guide biomarker development and rational immunotherapeutic strategies.

Related

  1. Number of examined lymph nodes and overall survival in intrahepatic cholangiocarcinoma: a population-based study suggesting a staging benefit
    Xuchang He, Wenhui An, Yangwei Chen +3
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. OLFM4 promotes intrahepatic cholangiocarcinoma progression through a PKM2-glycolysis-histone lactylation feedback loop.
    Shuochen Liu, Kai Cao, Changan Chen +11
    International journal of biological sciencesPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Same organ, divergent immunity: T-cell exhaustion versus stromal exclusion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    YanXi Chen, Tao Peng, Hao Nie +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  4. Intrahepatic Cholangiocarcinoma Staging and Classification Systems: An Updated Narrative Review.
    Andrea Marchese, Simone Conci, Laura Alaimo +4
    Journal of gastrointestinal cancerPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  5. Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.
    Yingying Hang, Lu Bai, Hsiquan Hsu +7
    The oncologistPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC

Cite

BibTeXRIS
BibTeX
@article{yan2026singlecell,
  title = {{Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications}},
  author = {Yanan Yan and Tianhao Teng and Xinying Luo and Jingfeng Liu and Jianmin Wang},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1918458},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1918458/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications
AU  - Yanan Yan
AU  - Tianhao Teng
AU  - Xinying Luo
AU  - Jingfeng Liu
AU  - Jianmin Wang
PY  - 2026
DA  - 2026/10/20
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1918458
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1918458/full
AB  - Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy characterized by pronounced cellular, spatial, and metabolic heterogeneity. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) are beginning to resolve this complexity by linking malignant, immune, stromal, and metabolic states to their tissue context. This review synthesizes recent single-cell and spatial studies of iCCA across four spatial contexts: adaptive immune regions containing tertiary lymphoid structures (TLSs), barriers formed by stromal and myeloid cells at the invasive front, myeloid niches shaped by hypoxia, and metastatic ecosystems involving immune and stromal cells. These niches connect tumor heterogeneity with immune regulation, stromal remodeling, metabolic adaptation, and therapeutic vulnerability. We also evaluate how crosstalk between metabolism and immunity shapes macrophage polarization, T-cell dysfunction, and treatment response, while distinguishing computationally inferred interactions from functionally supported mechanisms. The field is therefore moving from cataloging additional cell states and spatial niches toward establishing which ecosystem features are reproducible across cohorts, mechanistically supported, clinically measurable, and informative for treatment response. Current evidence supports a view of iCCA as a spatially organized and metabolically regulated tumor ecosystem that can guide biomarker development and rational immunotherapeutic strategies.
SN  - 1664-3224
ER  -